Thrombospondin-1 supports blood pressure by limiting eNOS activation and endothelial-dependent vasorelaxation

Cardiovascular Research

Volumn 88, Issue 3, 2010, Pages 471-481

  Bauer, Eileen M ^a   Qin, Yan ^c   Miller, Thomas W ^d   Bandle, Russell W ^d   Csanyi, Gabor ^a   Pagano, Patrick J ^a,b   Bauer, Philip M ^b   Schnermann, Jurgen ^c   Roberts, David D ^d   Isenberg, Jeff S ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Blood pressure; CD47; eNOS; Thrombospondin 1; Vasorelaxation

Indexed keywords

ACETYLCHOLINE; ANTIBODY; CD47 ANTIGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; PHENYLEPHRINE; THROMBOSPONDIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY CONSTRICTION; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR FUNCTION; COMPARATIVE STUDY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; HEART MUSCLE BLOOD FLOW; MALE; MEAN ARTERIAL PRESSURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; WILD TYPE;

ACETYLCHOLINE; ANIMALS; ANTIBODIES; ANTIGENS, CD47; BLOOD PRESSURE; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; HUMANS; MICE; MODELS, ANIMAL; NITRIC OXIDE SYNTHASE TYPE III; PHENYLEPHRINE; THROMBOSPONDIN 1; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION; VASODILATOR AGENTS;

EID: 78149288324     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq218     Document Type: Article

References (45)

1. Dudzinski DM, Michel T. Life history of eNOS: partners and pathways. Cardiovasc Res 2007;75:247-260.
2. Dudzinski DM, Igarashi J, Greif D, Michel T. The regulation and pharmacology of endothelial nitric oxide synthase. Annu Rev Pharmacol Toxicol 2006;46:235-276.
3. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004;109:II27-II33.
4. 2+ sensitization of contraction in vascular smooth muscle. J Biol Chem 2000;275: 21722-21729.
5. Isenberg JS, Ridnour LA, Perruccio EM, Espey MG, Wink DA, Roberts DD. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. Proc Natl Acad Sci USA 2005;102:13141-13146.
6. Isenberg JS, Wink DA, Roberts DD. Thrombospondin-1 antagonizes nitric oxide-stimulated vascular smooth muscle cell responses. Cardiovasc Res 2006;71: 785-793.
7. Isenberg JS, Romeo MJ, Yu C, Yu CK, Nghiem K, Monsale J et al. Thrombospondin-1 stimulates platelet aggregation by blocking the antithrombotic activity of nitric oxide/ cGMP signaling. Blood 2008;111:613-623.
8. Isenberg JS, Hyodo F, Matsumoto K, Romeo MJ, Abu-Asab M, Tsokos M et al. Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation. Blood 2007;109:1945-1952.
9. Isenberg JS, Qin Y, Maxhimer JB, Sipes JM, Despres D, Schnermann J et al. Thrombospondin-1 and CD47 regulate blood pressure and cardiac responses to vasoactive stress. Matrix Biol 2009;28:110-119.
10. Roberts DD, Cashel J, Guo N. Purification of thrombospondin from human platelets. J Tissue Cult Methods 1994;16:217-222.
11. Kao KJ, Klein PA. A monoclonal antibody-based enzyme-linked immunosorbent assay for quantitation of plasma thrombospondin. Am J Clin Pathol 1986;86:317-323.
12. Tan BK, Syed F, Lewandowski KC, O'Hare JP, Randeva HS. Circadian oscillation of circulating prothrombotic thrombospondin-1: ex vivo and in vivo regulation by insulin. J Thromb Haemost 2008;6:1827-1830.
13. Figueroa XF, Gonzalez DR, Martinez AD, Duran WN, Boric MP. ACh-induced endo-thelial NO synthase translocation, NO release and vasodilatation in the hamster microcirculation in vivo. J Physiol 2002;544:883-896.
14. Fulton D, Ruan L, Sood SG, Li C, Zhang Q, Venema RC. Agonist-stimulated endo-thelial nitric oxide synthase activation and vascular relaxation. Role of eNOS phos-phorylation at Tyr83. Circ Res 2008;102:497-504.
15. Fleming I, Busse R. Signal transduction of eNOS activation. Cardiovasc Res 1999;43: 532-541.
16. 2+ signalling. Pflugers Arch 1999;438:612-620.
17. Danthuluri NR, Cybulsky MI, Brock TA. ACh-induced calcium transients in primary cultures of rabbit aortic endothelial cells. Am J Physiol 1988;255:H1549-H1553.
18. Ghigo D, Alessio P, Foco A, Bussolino F, Costamagna C, Heller R et al. Nitric oxide synthesis is impaired in glutathione-depleted human umbilical vein endothelial cells. Am J Physiol 1993;265:C728-C732.
19. Gentile MT, Vecchione C, Maffei A, Aretini A, Marino G, Poulet R et al. Mechanisms of soluble beta-amyloid impairment of endothelial function. J Biol Chem 2004;279: 48135-48142.
20. Chatterjee A, Black SM, Catravas JD. Endothelial nitric oxide (NO) and its pathophy-siologic regulation. Vascul Pharmacol 2008;49:134-140.
21. Miike T, Shirahase H, Kanda M, Kunishiro K, Kurahashi K. Regional heterogeneity of substance P-induced endothelium-dependent contraction, relaxation, and-independent contraction in rabbit pulmonary arteries. Life Sci 2008;83:810-814.
22. Masaki T, Yanagisawa M, Takuwa Y, Kasuya Y, Kimura S, Goto K. Cellular mechanism of vasoconstriction induced by endothelin. Adv Second Messenger Phosphoprotein Res 1990;24:425-428.
23. Marin J, Sanchez-Ferrer CF. Role of endothelium-formed nitric oxide on vascular responses. Gen Pharmacol 1990;21:575-587.
24. Busse R, Pohl U, Mulsch A, Bassenge E. Modulation of the vasodilator action of SIN-1 by the endothelium. J Cardiovasc Pharmacol 1989;14(Suppl. 11):S81-S85.
25. Ralevic V, Mathie RT, Alexander B, Burnstock G. NG-nitro-L-arginine methyl ester attenuates vasodilator responses to acetylcholine but enhances those to sodium nitroprusside. J Pharm Pharmacol 1991;43:871-874.
26. Volpert OV, Lawler J, Bouck NP. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc Natl Acad Sci USA 1998;95:6343-6348.
27. Bayraktar M, Dundar S, Kirazli S, Teletar F. Platelet factor 4, beta-thromboglobulin and thrombospondin levels in type I diabetes mellitus patients. J Int Med Res 1994; 22:90-94.
28. Lutz J, Huwiler KG, Fedczyna T, Lechman TS, Crawford S, Kinsella TR et al. Increased plasma thrombospondin-1 (TSP-1) levels are associated with the TNF alpha-308A allele in children with juvenile dermatomyositis. Clin Immunol 2002;103:260-263.
29. Macko RF, Gelber AC, Young BA, Lowitt MH, White B, Wigley FM et al. Increased circulating concentrations of the counteradhesive proteins SPARC and thrombospondin-1 in systemic sclerosis (scleroderma). Relationship to platelet and endothelial cell activation. J Rheumatol 2002;29:2565-2570.
30. Browne P, Shalev O, Hebbel RP. The molecular pathobiology of cell membrane iron: the sickle red cell as a model. Free Radic Biol Med 1998;24:1040-1048.
31. Isenberg JS, Ridnour LA, Dimitry J, Frazier WA, Wink DA, Roberts DD. CD47 is necessary for inhibition of nitric oxide-stimulated vascular cell responses by thrombospondin-1. J Biol Chem 2006;281:26069-26080.
32. Cheung DW, Chen G. Calcium activation of hyperpolarization response to acetyl-choline in coronary endothelial cells. J Cardiovasc Pharmacol 1992;20(Suppl. 12): S120-S123.
33. 2+ in relation to generation of acetylcholine-induced endothelium-dependent hyperpolarization in rat mesenteric artery. Br J Pharmacol 1997;120:1328-1334.
34. Moncada S, Higgs EA. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J 1995;9:1319-1330.
35. Landry Y, Niederhoffer N, Sick E, Gies JP. Heptahelical and other G-protein-coupled receptors (GPCRs) signaling. Curr Med Chem 2006;13:51-63.
36. Brown EJ, Frazier WA. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 2001;11:130-135.
37. Schwartz MA, Brown EJ, Fazeli B. A 50-kDa integrin-associated protein is required for integrin-regulated calcium entry in endothelial cells. J Biol Chem 1993;268: 19931-19934.
38. 2+ influx by stimulating store-regulated cation entry and not by a direct action at the plasma membrane. Biochem J 1994; 300(Pt 3):665-672.
39. 2+ entry in confluent human umbilical vein endothelial cell cultures. J Biol Chem 1991;266:4251-4256.
40. Crews DE, Williams SR. Molecular aspects of blood pressure regulation. Hum Biol 1999;71:475-503.
41. Joyner MJ, Charkoudian N, Wallin BG. A sympathetic view of the sympathetic nervous system and human blood pressure regulation. Exp Physiol 2008;93:715-724.
42. Sakai H, Hara H, Tsai AG, Tsuchida E, Intaglietta M. Constriction of resistance arteries determines L-NAME-induced hypertension in a conscious hamster model. Microvasc Res 2000;60:21-27.
43. Swislocki A, Eason T, Kaysen GA. Oral administration of the nitric oxide biosynthesis inhibitor, N-nitro-L-arginine methyl ester (L-NAME), causes hypertension, but not glucose intolerance or insulin resistance, in rats. Am J Hypertens 1995;8:1009-1014.
44. Kosugi T, Heinig M, Nakayama T, Connor T, Yuzawa Y, Li Q et al. Lowering blood pressure blocks mesangiolysis and mesangial nodules, but not tubulointerstitial injury, in diabetic eNOS knockout mice. Am J Pathol 2009;174:1221-1229.
45. Liu Z, Zhao Q, Han Q, Gao M, Zhang N. Serum thrombospondin-1 is altered in patients with hemorrhagic fever with renal syndrome. J Med Virol 2008;80: 1799-1803.